Sanofi-aventis and Regeneron announced results from a Phase 3 study of aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer. This was a multinational, randomized, double-blind trial comparing aflibercept versus placebo in combination with docetaxel patients with locally advanced or metastatic nonsquamous NSCLC who have failed one platinum-based therapy.
The data showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the prespecified criteria for the primary endpoint of improvement in overall survival compared with a regimen of docetaxel + placebo (HR=1.01, CI: 0.868 to 1.174). The addition of aflibercept to docetaxel demonstrated activity as measured by key secondary endpoints of the study: progression-free survival (HR=0.82, CI: 0.716 to 0.937) and an overall objective response rate of 23.3% in the aflibercept arm compared with 8.9% in the placebo arm.
Aflibercept is an antiangiogenesis fusion protein that binds all forms of vascular endothelial growth factor-A (VEGF-A), VEGF-B and placental growth factor (PIGF), additional angiogenic growth factors that appear to play a role in tumor angiogenesis and inflammation. Aflibercept has been shown to bind VEGF-A, VEGF-B and PlGF with higher affinity than their natural receptors.
For more information call (877) REGN-777 or visit www.regeneron.com.